Pyxis Oncology Updates Phase 1 Trial Enrollment

Pyxis Oncology ( (PYXS) ) has issued an update.

On July 31, 2025, Pyxis Oncology revised patient enrollment for its Phase 1 clinical trial of micvotabart pelidotin, a treatment for advanced solid tumors. The update aligns with industry practices and confirms previous guidance on the number of head and neck squamous cell carcinoma patients expected in the trial’s dose expansion phase.

The most recent analyst rating on (PYXS) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Pyxis Oncology stock, see the PYXS Stock Forecast page.

Spark’s Take on PYXS Stock

According to Spark, TipRanks’ AI Analyst, PYXS is a Neutral.

Pyxis Oncology’s score reflects ongoing financial challenges with significant cash burn and unprofitability. While there are positive developments with the strategic focus on its lead candidate, technical indicators suggest caution. Valuation remains unattractive due to negative earnings. The company’s future hinges on successful execution of its strategic initiatives.

To see Spark’s full report on PYXS stock, click here.

More about Pyxis Oncology

Pyxis Oncology is a company operating in the biotechnology industry, focusing on developing innovative cancer therapies. The company is engaged in clinical trials to evaluate the efficacy and safety of its therapeutic candidates, particularly targeting advanced solid tumors.

Average Trading Volume: 512,643

Technical Sentiment Signal: Sell

Current Market Cap: $68.14M

For a thorough assessment of PYXS stock, go to TipRanks’ Stock Analysis page.